Several studies have demonstrated a direct correlation between CD133 expression and OS in various malignancies, including breast cancer, esophageal cancer, glioblastoma, osteosarcoma, hepatocellular carcinoma and CRC [67,80,81,82,83,84,85]. This evidence concerns the gene PROM1 and breast cancer.